BioCentury on BioBusiness,
Product Discovery & Development
Exelixis: Cabozantinib will vie with AstraZeneca's Caprelsa in thyroid cancer
Mixed messages in MTC
Monday, June 4, 2012
Updated Phase III data for Exelixis
Inc.'s cabozantinib showed the compound did not improve survival in
patients with medullary thyroid cancer, but the biotech says the data are not
mature and that PFS and safety data suggest its compound could be competitive
plc's Caprelsa vandetanib.
About 2,000 patients are
diagnosed with MTC in the U.S. each year. The initial treatment is removal of
the thyroid, after which some patients may have relatively indolent disease and
others will experience highly progressive metastatic disease over the course of
months. The exact proportion of patients with highly progressive disease is unknown.
words displayed of
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2017 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial Subscription 4 Weeks of Access
BioCentury's Weekly Business Intelligence Journal
Get a 4-week free trial subscription to BioCentury.
Get 4 Weeks Free
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]